Adjuvant chemotherapy in T1a/bN0 HER2-positive or triple-negative breast cancers: Application and outcomes

被引：17

作者：

Migdady, Yazan ^{[1
,2
]}

Sakr, Bachir J. ^{[1
,3
]}

Sikov, William M. ^{[1
,4
]}

Olszewski, Adam J. ^{[1
,2
]}

机构：

[1] Brown Univ, Warren Alpert Med Sch, Providence, RI 02912 USA

[2] Brown Univ, Mem Hosp Rhode Isl, Ctr Canc, Pawtucket, RI 02860 USA

[3] Women & Infants Hosp Rhode Isl, Program Womens Oncol, Providence, RI 02905 USA

[4] Miriam Hosp, Providence, RI 02906 USA

来源：

BREAST | 2013年 / 22卷 / 05期

关键词：

Stage I breast cancer; HER2-positive; Triple-negative; Adjuvant chemotherapy; ONE CENTIMETER; 1; CM; PROGNOSIS; TRASTUZUMAB; WOMEN; SURVIVAL; RECURRENCE; CARCINOMA; RECEPTOR; THERAPY;

D O I：

10.1016/j.breast.2013.02.014

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

We assessed practice patterns and the impact of systemic adjuvant therapy on human epidermal growth factor receptor 2 (HER2)-positive or triple-negative, node-negative breast cancers up to 10 mm in size. Records of 161 patients identified among 1415 cases diagnosed in our institutions between 2000 and 2010 were assessed for factors associated with recommendation for chemotherapy and survival outcomes. Adjuvant chemotherapy was recommended in 53% of patients, more commonly in patients with younger age, stage T1b, high grade, HER2+/ER- status and diagnosis after 2006. With a median follow-up of 54 months, the 5-year cumulative incidence of recurrence was 5.3% and overall survival was 93.2%. Age less than 40 and presence of lymphovascular invasion (LVI) were associated with higher risk of recurrence. In a univariate analysis administration of adjuvant chemotherapy was not associated with a significantly better recurrence rate (P = 0.33). (C) 2013 Elsevier Ltd. All rights reserved.

引用

页码：793 / 798

页数：6

共 32 条

[1] Prognosis and Outcome of Small (≤1 cm), Node-Negative Breast Cancer on the Basis of Hormonal and HER-2 Status [J].

Amar, Surabhi ;

McCullough, Ann E. ;

Tan, Winston ;

Geiger, Xochiquetzal J. ;

Boughey, Judy C. ;

McNeil, Rebecca B. ;

Coppola, Kyle E. ;

McLaughlin, Sarah A. ;

Palmieri, Frances M. ;

Perez, Edith A. .

ONCOLOGIST, 2010, 15 (10) :1043-1049

[2] Elucidating Prognosis and Biology of Breast Cancer Arising in Young Women Using Gene Expression Profiling [J].

Azim, Hatem A., Jr. ;

Michiels, Stefan ;

Bedard, Philippe L. ;

Singhal, Sandeep K. ;

Criscitiello, Carmen ;

Ignatiadis, Michail ;

Haibe-Kains, Benjamin ;

Piccart, Martine J. ;

Sotiriou, Christos ;

Loi, Sherene .

CLINICAL CANCER RESEARCH, 2012, 18 (05) :1341-1351

[3] Prognosis in women with small (T1mic,T1a,T1b) node-negative operable breast cancer by immunohistochemically selected subtypes [J].

Cancello, G. ;

Maisonneuve, P. ;

Rotmensz, N. ;

Viale, G. ;

Mastropasqua, M. G. ;

Pruneri, G. ;

Montagna, E. ;

Dellapasqua, S. ;

Iorfida, M. ;

Cardillo, A. ;

Veronesi, P. ;

Luini, A. ;

Intra, M. ;

Gentilini, O. ;

Scarano, E. ;

Goldhirsch, A. ;

Colleoni, M. .

BREAST CANCER RESEARCH AND TREATMENT, 2011, 127 (03) :713-720

[4] Prognosis and adjuvant treatment effects in selected breast cancer subtypes of very young women (<35 years) with operable breast cancer [J].

Cancello, G. ;

Maisonneuve, P. ;

Rotmensz, N. ;

Viale, G. ;

Mastropasqua, M. G. ;

Pruneri, G. ;

Veronesi, P. ;

Torrisi, R. ;

Montagna, E. ;

Luini, A. ;

Intra, M. ;

Gentilini, O. ;

Ghisini, R. ;

Goldhirsch, A. ;

Colleoni, M. .

ANNALS OF ONCOLOGY, 2010, 21 (10) :1974-1981

[5] Invasive Breast Cancer [J].

Carlson, Robert W. ;

Allred, Craig ;

Anderson, Benjamin O. ;

Burstein, Harold J. ;

Carter, W. Bradford ;

Edge, Stephen B. ;

Erban, John K. ;

Farrar, William B. ;

Forero, Andres ;

Giordano, Sharon Hermes ;

Goldstein, Lori J. ;

Gradishar, William J. ;

Hayes, Daniel F. ;

Hudis, Clifford A. ;

Ljung, Britt-Marie ;

Mankoff, David A. ;

Marcom, P. Kelly ;

Mayer, Ingrid A. ;

McCormick, Beryl ;

Pierce, Lori J. ;

Reed, Elizabeth C. ;

Sachdev, Jasgit ;

Smith, Mary Lou ;

Somlo, George ;

Ward, John H. ;

Wolff, Antonio C. ;

Zellars, Richard .

JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2011, 9 (02) :136-222

[6] Ki67 Index, HER2 Status, and Prognosis of Patients With Luminal B Breast Cancer [J].

Cheang, Maggie C. U. ;

Chia, Stephen K. ;

Voduc, David ;

Gao, Dongxia ;

Leung, Samuel ;

Snider, Jacqueline ;

Watson, Mark ;

Davies, Sherri ;

Bernard, Philip S. ;

Parker, Joel S. ;

Perou, Charles M. ;

Ellis, Matthew J. ;

Nielsen, Torsten O. .

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2009, 101 (10) :736-750

[7] Clinical Relevance of HER2 Overexpression/Amplification in Patients With Small Tumor Size and Node-Negative Breast Cancer [J].

Curigliano, Giuseppe ;

Viale, Giuseppe ;

Bagnardi, Vincenzo ;

Fumagalli, Luca ;

Locatelli, Marzia ;

Rotmensz, Nicole ;

Ghisini, Raffaella ;

Colleoni, Marco ;

Munzone, Elisabetta ;

Veronesi, Paolo ;

Zurrida, Stefano ;

Nole, Franco ;

Goldhirsch, Aron .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (34) :5693-5699

[8] Choice and interpretation of statistical tests used when competing risks are present [J].

Dignam, James J. ;

Kocherginsky, Maria N. .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (24) :4027-4034

[9] A proportional hazards model for the subdistribution of a competing risk [J].

Fine, JP ;

Gray, RJ .

JOURNAL OF THE AMERICAN STATISTICAL ASSOCIATION, 1999, 94 (446) :496-509

[10] Tamoxifen, radiation therapy, or both for prevention of ipsilateral breast tumor recurrence after lumpectomy in women with invasive breast cancers of one centimeter or less [J].

Fisher, B ;

Bryant, J ;

Dignam, JJ ;

Wickerham, DL ;

Mamounas, EP ;

Fisher, ER ;

Margolese, RG ;

Nesbitt, L ;

Paik, S ;

Pisansky, TM ;

Wolmark, N .

JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (20) :4141-4149

← 1 2 3 4 →